Pharmaceutical Executive-12-01-2005

Pharmaceutical Executive

PharmExec's 2006 Forecast

December 01, 2005

Special Reports

0

0

Medicare Part D launches. $23 billion worth of patents expire. FDA wrestles with safety issues. Pharma prepares for unprecedented cost cutting and restructuring. 2006 promises to be banner year-if you like roller coasters.

Thought Leader: A Q&A with Graham Allaway

December 01, 2005

Thought Leader

0

0

Some people are infected by HIV strains that are already resistant to FDA-approved drugs because they were transmitted by someone who developed resistance while receiving antiretroviral therapy. As a result, these patients often fail therapy.

So You Think You Know Pharma?

December 01, 2005

0

0

PharmExec's 2005 Pharma Knowledge Quiz

The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray?

December 01, 2005

Features

0

0

Like the course of a pandemic itself, the great avian influenza scare came in waves. In 1997, the first case of the now infamous H5N1 strain of bird flu emerged in Hong Kong, infecting 18 people and killing six. In late 2003 it struck again-more than 120 people fell ill and at least 60 died over the next two years. Then this fall, David Nabarro, MD, the UN coordinator for avian and human influenza, shocked everyone when he said a bird flu pandemic could claim up to 150 million lives-a figure the World Health Organization (WHO) quickly retracted.

Washington Report: Big Production

December 01, 2005

Washington Report

0

0

FDA may be receiving fewer new drug applications for truly innovative products, but it has been overwhelmed this year with 800 abbreviated NDAs for generic drugs and thousands of supplements.

Leadership: Where Have All the Heroes Gone?

December 01, 2005

Leadership

0

0

In an article for the New York Times, reporter Damien Cave pointed out how few heroes have been publicly recognized by the Administration in the current war. Despite the fact that there have been incredible acts of heroism and gutsy leadership on the ground of this Iraq war, the powers that be, for the most part, are calling no attention to it-at least no prime-time attention. Damien's most damning example came from Major Bruce Norton, a military historian and author of Encyclopedia of American Military Heroes, who recounted how a Marine recently received his Navy Cross, the second-highest military honor-not with ceremony and honor, but in the mail.

Inside DDMAC: A Conversation with Thomas Abrams

December 01, 2005

Features

0

0

Despite heightened scrutiny from industry advocates and the beginnings of self-imposed regulation, pharma companies' violations of DTC regulations have been getting worse, says Tom Abrams, director of FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC). Abrams has been on all sides of drug marketing, from receiving promotions as a pharmacist to creating promotions as a member of industry to regulating promotions as the head of DDMAC. As such, he's in good position to see the big picture.